Original articleGeneral thoracicExpression of Nuclear Factor-κB and Its Clinical Significance in Nonsmall-Cell Lung Cancer
Section snippets
Patients
Forty-five tumor tissue specimens were sampled from 45 patients with NSCLC who underwent surgery between October and December 2004. All patients were required to sign a written informed consent. Patients who received induction therapy were excluded from the study. Samples were histologically confirmed to have been obtained from tumor masses. A portion of each sample was frozen immediately after surgical resection and stored at –80°C until use. The clinicopathologic features of the specimens
Correlation With Clinical Characteristics
The Western blotting products from NF-κB protein were semiquantified using β-actin as an intrinsic control. The density of each band was separately converted to a numeric value by Bandleader software. The ratio of NF-κB to β-actin in each case was calculated. The average NF-κB/β-actin value was 0.6047 ± 0.3572 (Fig 1).
There was no significant correlation between NF-κB and patient age, sex, tumor staging, and pathologic type. Expression level of NF-κB was higher in poorly and moderately
Comment
The transcription factor NF-κB has been implicated in the control of cell proliferation and oncogenesis [6]. Nuclear factor-κB transcription factors bind to DNA as heterodimers or homodimers that are composed of five possible subunits in mouse and human (RelA/p65, c-Rel, RelB, p50, and p52). These proteins mediate DNA binding, dimerization, and interactions with inhibitory factors known as inhibitor κB (I-κB) proteins [7]. Degradation of the I-κB proteins results in the liberation of NF-κB,
References (19)
- et al.
Regional lymph node classification for lung cancer staging
Chest
(1997) - et al.
NF-kappaB as a therapeutic target in cancer
Trends Mol Med
(2002) - et al.
Modulation of antiapoptotic cell signaling pathways in non-small cell lung cancerthe role of NF-kappaB
Semin Thorac Cardiovasc Surg
(2004) - et al.
Caspase-3-mediated cleavage of the NF-kappa B subunit p65 at the NH2 terminus potentiates naphthoquinone analog-induced apoptosis
J Biol Chem
(2001) - et al.
NF-kappa B activation of p53A potential mechanism for suppressing cell growth in response to stress
J Biol Chem
(1994) - et al.
COX-2 inhibition and lung cancer
Semin Oncol
(2004) - et al.
Adenovirus-uteroglobin suppresses COX-2 expression via inhibition of NF-kappaB activity in lung cancer cells
Lung Cancer
(2005) - et al.
Chemoresistanceimpact of nuclear factor (NF)-kappaB inhibition by small interfering RNA
Clin Cancer Res
(2004) - et al.
Histological typing of lung and pleural tumorsInternational histological classification of tumors
(1999)
Cited by (54)
Assessing the selective therapeutic efficacy of superparamagnetic erlotinib nanoparticles in lung cancer by using quantitative magnetic resonance imaging and a nuclear factor kappa-B reporter gene system
2018, Nanomedicine: Nanotechnology, Biology, and MedicineCitation Excerpt :In this study, we used the dual-function EGFR-specific small-molecular inhibitor erlotinib conjugated to dextran-coated SPIO for monitoring the treatment responses and achieving effective treatment. Characteristics, stability, size, and zeta potential were validated in our previous study.18 Dextran-coated iron oxide NPs may reduce the cytotoxicity of iron oxide in an effective manner and are the most efficient coating material for iron NPs.39
Variant of BCL3 gene is strongly associated with five-year survival of non-small-cell lung cancer patients
2015, Lung CancerCitation Excerpt :In addition, BCL3 has been documented to be deregulated in a number of solid tumors including breast cancer [12–15], prostate cancer [16], nasopharygeal carcinomas [17], endometrial tumors [18] and colorectal cancer [19]. Although deregulation of p50, p52, p65 (RelA) and RelB has been reported in NSCLC [20–23], the role of BCL3 in NSCLC has not been investigated. Moreover, there is lack of information regarding the role of the single nucleotide polymorphism (SNP) rs8100239, an intronic tagging SNP, in cancer.
Nuclear factor κb and cyclooxygenase-2 immunoexpression in oral dysplasia and oral squamous cell carcinoma
2013, Annals of Diagnostic PathologyCitation Excerpt :A series of studies have found that NF-κB overexpression may be involved in the development and progression of malignant processes from different sites such as the prostate, breast, pancreas, oral cavity, urinary bladder, and others [7-10]. In addition, its nuclear expression has emerged as an independent prognosticator of adverse significance in various human cancers [10-13]. One of the downstream targets of NF-κB is cyclooxygenase-2 (COX-2), a key regulatory enzyme in the synthesis of prostaglandins (PGs) from arachidonic acid.
Induction of caspase mediated apoptosis and down-regulation of nuclear factor-κB and Akt signaling are involved in the synergistic antitumor effect of gemcitabine and the histone deacetylase inhibitor trichostatin A in human bladder cancer cells
2011, Journal of UrologyCitation Excerpt :NF-κB is a pleiotropic transcription factor that regulates the transcription of a large number of genes with key roles in the promotion, angiogenesis and metastasis of various malignant diseases.16 Also, emerging evidence suggest that the induction of NF-κB signaling is related to tumorigenesis and resistance to chemotherapeutic agents.17–21 In most unstimulated cells NF-κB protein resides in the cytoplasm in its inactive form and is bound to IκB proteins.
NF-κB Signaling in Tumor Pathways Focusing on Breast and Ovarian Cancer
2022, Oncology Reviews